PMID- 31094239
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20200811
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Linking)
VI  - 19
IP  - 5
DP  - 2019 May
TI  - Advances in preventing adverse events during monoclonal antibody management of 
      multiple sclerosis.
PG  - 417-429
LID - 10.1080/14737175.2019.1610393 [doi]
AB  - Decades of pharmacological research in Multiple Sclerosis (MS) led to the 
      development of therapeutic Monoclonal Antibodies (MAbs) with many different 
      mechanisms of action (MoA), potentially able to improve disability outcome but 
      also determining a more complex management of patients. Areas covered: When 
      clinicians select MS treatments, they should consider adverse events (AEs) on 
      individual basis to minimize patients' risks. Some AEs are common and can be 
      easily handled, but rare complications should also be taken into account. The aim 
      of this review is to summarize existing evidence and provide practical 
      recommendations for the management of therapeutic MAbs in MS. Expert opinion: The 
      introduction of MAbs revolutionized MS treatment with an improvement in 
      effectiveness. Unfortunately, this has been coupled with a more complex array of 
      AEs needing a tighter surveillance strategy. A close interaction between general 
      practitioners, neurologists, and other specialists is the key for a safer use of 
      such effective drugs.
FAU - De Giglio, Laura
AU  - De Giglio L
AD  - a MS Center Sant'Andrea Hospital, Sapienza University of Rome , Rome , Italy.
AD  - b Department of Human Neuroscience , Sapienza University of Rome , Rome , Italy.
FAU - Grimaldi, Alessandro E
AU  - Grimaldi AE
AD  - a MS Center Sant'Andrea Hospital, Sapienza University of Rome , Rome , Italy.
FAU - Fubelli, Federica
AU  - Fubelli F
AD  - a MS Center Sant'Andrea Hospital, Sapienza University of Rome , Rome , Italy.
FAU - Marinelli, Fabiana
AU  - Marinelli F
AD  - c MS Center Fabrizio Spaziani Hospital , Frosinone , Italy.
FAU - Pozzilli, Carlo
AU  - Pozzilli C
AD  - a MS Center Sant'Andrea Hospital, Sapienza University of Rome , Rome , Italy.
AD  - b Department of Human Neuroscience , Sapienza University of Rome , Rome , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190516
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Drug-Related Side Effects and Adverse Reactions/*prevention & control
MH  - Humans
MH  - Immunologic Factors/*adverse effects
MH  - Multiple Sclerosis/*drug therapy
OTO - NOTNLM
OT  - Monoclonal antibodies
OT  - alemtuzumab
OT  - disease-modifying therapies
OT  - multiple sclerosis
OT  - natalizumab
OT  - ocrelizumab
EDAT- 2019/05/17 06:00
MHDA- 2020/08/12 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
PHST- 2019/05/17 06:00 [entrez]
AID - 10.1080/14737175.2019.1610393 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2019 May;19(5):417-429. doi: 10.1080/14737175.2019.1610393. 
      Epub 2019 May 16.